Waldron, J. A.; Kanellos, G.; Smith, R. C. L.; Knight, J. R. P.; Munro, J.; Alexandrou, C.; Vlahov, N.; Pardo-Fernandez, L.; Moore, M.; Gillen, S. L.; Strathdee, D.; Stevenson, D.; Warrander, F. C.; Gilroy, K.; Nixon, C.; Cadden, B.; Powley, I.; Officer-Jones, L.; Ballantyne, F.; Hay, J.; Pennel, K.; Edwards, J.; Campbell, A. D.; Ridgway, R. A.; Coffelt, S. B.; Norman, J.; Le Quesne, J.; Bushell, M.; Sansom, O. J.

Dysregulated translation is a hallmark of cancer. Targeting the translational machinery represents a therapeutic avenue which is being actively explored. eIF4A inhibitors target both eIF4A1, which promotes translation as part of the eIF4F complex, and eIF4A2, which can repress translation via the CCR4 NOT complex. While high eIF4A1 expression is associated with poor patient outcome, the role of eIF4A2 in cancer remains unclear. Furthermore, the on-target toxicity of targeting specific eIF4A paralogues in healthy tissue is under explored. We show that while loss of either paralogue is tolerated in the wild-type intestine, eIF4A1 is specifically required to support the translational demands of oncogenic Wnt signalling. Intestinal tumourigenesis is suppressed in colorectal cancer models following loss of eIF4A1 but accelerated following loss of eIF4A2, while eIF4A inhibition with eFT226 mimics loss of eIF4A1 in these models.